April 16, 2025CorporateTerumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerDaly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth
April 16, 2025CorporateTerumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US– Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort –
April 01, 2025FinancialTerumo announces changes to the names of some businesses within the Cardiac and Vascular Company (PDF 117.21 KB) Disclosure segments of Blood and Cell Technologies Company to also be revised
2023 All pages, single page (PDF 11.47 MB) All pages, 2 pages spread (PDF 11.43 MB) 2022 All pages, single page (PDF 13.04 MB) All pages, 2 pages spread (PDF 12.89 MB) Please refer to the ESG Section here.2021 All pages, single page (PDF 22.85 MB) All pages, 2 pages spread (PDF 22.77 MB) 2020 Japanese (PDF 3.47 MB) English (PDF 3 MB) Financial Information (English) (PDF 1.48 MB) 2019 Japanese (PDF 3.36 MB) English (PDF 2.92 MB) Financial Information (English) (PDF 1.5 MB) 2018 Japanese (PDF 2.23 MB) English (PDF 1.97 MB) Financial Information (English) (PDF 1.72 MB) 2017 Japanese (PDF 7.59 MB) English (PDF 6.53 MB) Financial Information (English) (PDF 2.93 MB) DisclaimerAdobe Reader is required for viewing PDF files.Download Adobe Reader
Top
Top